Principia Biopharma, Inc.   Report issue

For profit Phase 1 Phase 3
Founded: South San Francisco United States (2008)
Status: Acquired by Sanofi-Aventis (2020)

Organization Overview

First Clinical Trial
2015
NCT02608125
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Principia Biopharma | Principia Biopharma Australia Pty Ltd. | Principia Biopharma Inc. | Principia Biopharma, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Rilzabrutinib (4 trials)

Drugs in Phase 1 Trials (1)

prn1371 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Immunoglobulin G4-Related Disease (Phase 2)

Pemphigus (Phase 3)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Thrombocytopenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2